PMID- 28816938
OWN - NLM
STAT- MEDLINE
DCOM- 20170905
LR  - 20221222
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 33
DP  - 2017 Aug
TI  - Advanced glycation end products promote ChREBP expression and cell proliferation 
      in liver cancer cells by increasing reactive oxygen species.
PG  - e7456
LID - 10.1097/MD.0000000000007456 [doi]
LID - e7456
AB  - The aim of the study was to elucidate the mechanism by which advanced glycation 
      end products (AGEs) promote cell proliferation in liver cancer cells.We treated 
      liver cancer HepG2 cells with 200 mg/L AGEs or bovine serum albumin (BSA) and 
      assayed for cell viability, cell cycle, and apoptosis. We performed real-time PCR 
      and Western blot analysis for RNA and protein levels of carbohydrate responsive 
      element-binding protein (ChREBP) in AGEs- or BSA-treated HepG2 cells. We analyzed 
      the level of reactive oxygen species (ROS) in HepG2 cells treated with AGEs or 
      BSA.We found that increased S-phase cell percentage and decreased apoptosis 
      contributed to AGEs-induced liver cancer cell proliferation. Real-time PCR and 
      Western blot analysis showed that AGEs stimulated RNA and protein levels of 
      ChREBP, a transcription factor promoting glycolysis and maintaining cell 
      proliferation in liver cancer cells. Intriguingly, the level of ROS was higher in 
      AGEs-treated liver cancer cells. Treating liver cancer cells with antioxidant 
      N-acetyl cystein (NAC) partly blocked AGEs-induced ChREBP expression and cell 
      proliferation.Our results suggest that the AGEs-ROS-ChREBP pathway plays a 
      critical role in promoting ChREBP expression and liver cancer cell proliferation.
FAU - Chen, Hanbei
AU  - Chen H
AD  - Department of Endocrinology, Xinhua Hospital Department of Biochemistry and 
      Molecular Cell Biology, Shanghai Key Laboratory for Tumor Microenvironment and 
      Inflammation, Key Laboratory of Cell Differentiation and Apoptosis of Chinese 
      Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai 
      State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell 
      Signaling Network, School of Life Sciences, Xiamen University, Xiamen, Fujian 
      Department of Gastroenterology, Xinhua Hospital, Shanghai Jiao Tong University 
      School of Medicine, Shanghai, China.
FAU - Li, Yakui
AU  - Li Y
FAU - Zhu, Yemin
AU  - Zhu Y
FAU - Wu, Lifang
AU  - Wu L
FAU - Meng, Jian
AU  - Meng J
FAU - Lin, Ning
AU  - Lin N
FAU - Yang, Dianqiang
AU  - Yang D
FAU - Li, Minle
AU  - Li M
FAU - Ding, WenJin
AU  - Ding W
FAU - Tong, Xuemei
AU  - Tong X
FAU - Su, Qing
AU  - Su Q
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Basic Helix-Loop-Helix Leucine Zipper Transcription Factors)
RN  - 0 (Glycation End Products, Advanced)
RN  - 0 (MLXIPL protein, human)
RN  - 0 (RNA, Messenger)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (Transcription Factors)
RN  - WYQ7N0BPYC (Acetylcysteine)
SB  - IM
EIN - Medicine (Baltimore). 2017 Dec;96(50):e9318. PMID: 29390398
MH  - Acetylcysteine/pharmacology
MH  - Apoptosis
MH  - Basic Helix-Loop-Helix Leucine Zipper Transcription Factors/*biosynthesis
MH  - Carcinoma, Hepatocellular/*metabolism
MH  - Cell Proliferation
MH  - Cell Survival
MH  - Glycation End Products, Advanced/*pharmacokinetics
MH  - Humans
MH  - Liver Neoplasms/*metabolism
MH  - RNA, Messenger/biosynthesis
MH  - Reactive Oxygen Species/*metabolism
MH  - Real-Time Polymerase Chain Reaction
MH  - Transcription Factors/metabolism
MH  - Tumor Cells, Cultured
PMC - PMC5571675
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2017/08/18 06:00
MHDA- 2017/09/07 06:00
PMCR- 2017/08/18
CRDT- 2017/08/18 06:00
PHST- 2017/08/18 06:00 [entrez]
PHST- 2017/08/18 06:00 [pubmed]
PHST- 2017/09/07 06:00 [medline]
PHST- 2017/08/18 00:00 [pmc-release]
AID - 00005792-201708180-00005 [pii]
AID - MD-D-16-04689 [pii]
AID - 10.1097/MD.0000000000007456 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Aug;96(33):e7456. doi: 10.1097/MD.0000000000007456.